GR3023614T3 - Use of human igf-i - Google Patents

Use of human igf-i

Info

Publication number
GR3023614T3
GR3023614T3 GR970401258T GR970401258T GR3023614T3 GR 3023614 T3 GR3023614 T3 GR 3023614T3 GR 970401258 T GR970401258 T GR 970401258T GR 970401258 T GR970401258 T GR 970401258T GR 3023614 T3 GR3023614 T3 GR 3023614T3
Authority
GR
Greece
Prior art keywords
treatment
prevention
human igf
cardiac
medicament
Prior art date
Application number
GR970401258T
Other languages
English (en)
Inventor
Peter Gluckman
Anna Skottner
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of GR3023614T3 publication Critical patent/GR3023614T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GR970401258T 1991-01-11 1997-05-30 Use of human igf-i GR3023614T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9100099A SE9100099D0 (sv) 1991-01-11 1991-01-11 Use of growth factor
PCT/SE1992/000009 WO1992011865A1 (en) 1991-01-11 1992-01-10 Use of human igf-i

Publications (1)

Publication Number Publication Date
GR3023614T3 true GR3023614T3 (en) 1997-08-29

Family

ID=20381598

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970401258T GR3023614T3 (en) 1991-01-11 1997-05-30 Use of human igf-i

Country Status (16)

Country Link
US (1) US5434134A (el)
EP (2) EP0566641B1 (el)
JP (1) JP3566283B2 (el)
AT (1) ATE150316T1 (el)
AU (1) AU657729B2 (el)
CA (1) CA2099257A1 (el)
DE (1) DE69218406T2 (el)
DK (1) DK0566641T3 (el)
ES (1) ES2101833T3 (el)
GR (1) GR3023614T3 (el)
IE (1) IE914392A1 (el)
IL (1) IL100585A (el)
NZ (1) NZ241108A (el)
SE (1) SE9100099D0 (el)
WO (1) WO1992011865A1 (el)
ZA (1) ZA919977B (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US5661122A (en) * 1994-04-15 1997-08-26 Genentech, Inc. Treatment of congestive heart failure
US5935924A (en) * 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
WO1996010401A1 (en) * 1994-10-04 1996-04-11 Emory University Methods for regulation of insulin-like growth factor i receptor
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
GB9605124D0 (en) 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
EP1566180A3 (en) * 1996-08-30 2007-08-08 Eli Lilly & Company Use of GLP-1 or Analogs in Treatment of Myocardial Infarction
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6335317B1 (en) 1998-04-10 2002-01-01 Emory University Use of gut-trophic growth factors to improve oxidative status
US6300271B1 (en) * 1998-05-18 2001-10-09 Phillips Petroleum Company Compositions that can produce polymers
US7368420B1 (en) 1998-10-02 2008-05-06 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Akt compositions for enhancing survival of cells
EP1117426B1 (en) * 1998-10-02 2005-12-07 Caritas St. Elizabeth's Medical Center of Boston, Inc. Akt compositions for enhancing survival of cardiomyocytes
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
SE9901634D0 (sv) * 1999-05-05 1999-05-05 Sahltech Ab Treatment of myocardial infarction with a substance related to the growth hormone axis
GB0011278D0 (en) 2000-05-10 2000-06-28 Univ London Repair of nerve damage
ATE389416T1 (de) 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
US7862810B2 (en) * 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20110091428A1 (en) * 2000-07-31 2011-04-21 New York Medical College Compositions of adult organ stem cells and uses thereof
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20020061587A1 (en) 2000-07-31 2002-05-23 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002032449A2 (en) * 2000-10-13 2002-04-25 Chiron Corporation Method for treating ischemic events affecting the central nervous system
EP1358209B1 (en) 2001-02-09 2006-12-27 Genentech, Inc. Crystallization of igf-1
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
GB0426154D0 (en) * 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
WO2006076342A2 (en) * 2005-01-11 2006-07-20 Heart Failure Technologies, Inc. Method and system for treating heart failure
EP1846021A2 (en) * 2005-02-08 2007-10-24 Japan As Represented By The President Of National Cardiovascular Center Novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (igf-1)
US8119123B2 (en) 2006-02-16 2012-02-21 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
WO2009062143A2 (en) 2007-11-09 2009-05-14 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
WO2009073594A1 (en) 2007-11-30 2009-06-11 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
US20090162329A1 (en) * 2007-11-30 2009-06-25 Piero Anversa Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure
CA2743697A1 (en) * 2007-11-30 2009-06-11 New York Medical College Methods of isolating non-senescent cardiac stem cells and uses thereof
CN110812369A (zh) * 2018-08-10 2020-02-21 浙江楚沅生物科技有限公司 用于治疗组织坏死或改善心脏功能的药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272649A (en) * 1979-04-09 1981-06-09 Williams Electronics, Inc. Processor controlled sound synthesizer
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects

Also Published As

Publication number Publication date
AU1166992A (en) 1992-08-17
EP0501937A1 (en) 1992-09-02
ZA919977B (en) 1992-09-30
ATE150316T1 (de) 1997-04-15
JPH06504286A (ja) 1994-05-19
ES2101833T3 (es) 1997-07-16
DE69218406D1 (de) 1997-04-24
IL100585A0 (en) 1992-09-06
SE9100099D0 (sv) 1991-01-11
IL100585A (en) 1997-04-15
EP0501937B1 (en) 1997-03-19
EP0566641A1 (en) 1993-10-27
CA2099257A1 (en) 1992-07-12
WO1992011865A1 (en) 1992-07-23
DK0566641T3 (da) 1997-10-06
IE914392A1 (en) 1992-07-15
AU657729B2 (en) 1995-03-23
US5434134A (en) 1995-07-18
NZ241108A (en) 1997-06-24
EP0566641B1 (en) 1997-03-19
DE69218406T2 (de) 1997-07-10
JP3566283B2 (ja) 2004-09-15

Similar Documents

Publication Publication Date Title
IL100585A0 (en) Use of human igf-i
GR3036901T3 (en) Treatment of partial growth hormone insensitivity syndrome
FI932385A (fi) Behandling av osteoporos genom anvaendning av somatoliberin (GRF) i en kombination med paratyreoideahormon (PTH)
EP0476044A4 (en) Treating disorders by application of insulin-like growth factors and analogs
EP0552256A4 (el)
EP0464022A4 (en) Insulinotropic hormone
EP0703785A4 (en) METHODS FOR TREATING MUSCLE DISEASES AND MUSCLE DISORDER
CY1110287T1 (el) Χρηση της ανθρωπινης παραθυρεοειδους ορμονης
MY109309A (en) Improvements in or relating to somatostatins
GR3025003T3 (en) Bombesin analogs
ES2087337T3 (es) Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos.
DE69326122D1 (de) Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen
AR036591A1 (es) Uso de la hl en hiperestimulacion ovarica controlada
ATE104143T1 (de) Kombination von phenaethanolamin und wachstumshormon.
IL145403A0 (en) Fragments of virus protein 2 or 3 of the polyoma virus, use for transporting active ingredients
HU9201399D0 (en) Medical preparation containing diritromycine
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
RU93058426A (ru) Антогонист галанина, способ его получения, пептид, фармацевтический состав и способ лечения
UA10248A (uk) Спосіб лікування ішемічної хвороби серця на фоні цукрового діабету
MX9707904A (es) Analogos del factor de liberacion de la hormona del crecimiento.
DK119391A (da) Humaninsulinanaloger